Skip to main content
[Preprint]. 2021 Aug 25:2021.05.13.21257129. Originally published 2021 May 14. [Version 2] doi: 10.1101/2021.05.13.21257129

Extended Data Figure 2: Cellular and serological characterization of blood samples from control and cancer cohorts.

Extended Data Figure 2:

a, PBMC frequencies of blood samples at each timepoint. P-values were calculated by 2-way ANOVA in which individual samples across blood draws were paired. b, CD19+ B cell frequencies of blood samples at each timepoint. P-values were calculated by 2-way ANOVA in which individual samples across blood draws were paired. c, CD13+ myeloid cell frequencies of blood samples at each blood draw. P-values were calculated by 2-way ANOVA in which individual samples across draws were paired. d, B cell subset frequencies at each draw. e, Raw ELISA data for quantification of RBD titers shown in Figure 1d. A serum concentration beginning at 1:80 was serially diluted and area under the curve (AUC) values calculated. Lines connect the same individual at each dilution. Data from the third blood draw are shown for both the control and cancer cohort. *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001 by 2-way ANOVA.